NATURAL PRODUCT RESEARCH AND DEVELOPMENT ›› 2015, Vol. 27 ›› Issue (Suppl): 197-204. doi: 10.16333/j.1001-6880.2015.S.045

• Article • Previous Articles     Next Articles

GPR119:A Novel Therapeutic Receptor for Type 2 Diabetes and Obesity

SUN Feng-hui,WANG Pin-jia,CHENG Xi,LIN Lin,DAI Min*   

  1. Chengdu Medical College,Chengdu 610500,China
  • Online:2015-12-01 Published:2016-01-12

Abstract: Type 2 diabetes (T2D) is one of the leading causes of morbidity and mortality all over the world.Epidemiologic studies have demonstrated that the patients with obesity have increased risk of diabetes.A novel G protein coupled receptor(GPCR),GPR119,was identified and has emerged as arguably one of the most exciting targets for the treatment of T2D and obesity. In vitro and in vivo, GPR119 play a key role in modulating glucose homeostasis,food intake,weight loss.This review summarizes the research leading to the identification of GPR119 as a potential drug target for T2D and related metabolic disorders.In addition,an overview of the recent progress made in the discovery of orally active GPR119 agonists is provided.

Key words: GPR119, agonist, G protein-coupled receptor, Type 2 diabetes, Obesity

CLC Number: